Bob Zawada

Bob Zawada has over twenty years of experience in the field of assay development and operations. Bob began their career in 1999 as a Postdoctoral Assistant at Tularik, where they designed and optimized experimental protocols for a successful high-throughput screening (HTS) campaign. In 2000, they joined MelTec, GmbH as a Staff Scientist, where they were the project leader organizing and supervising biological experiments and report preparation for a $5M collaborative project. In 2004, they joined SelectX Pharmaceuticals as a Staff Scientist, where they oversaw independent laboratory coordinating molecular biology, cell culture, purification and assay development teams. In 2006, they joined BioAssay Systems as the Director of Assay Development and Service Projects Manager, where they expanded the product line from 30 to 180+ products and directly developed 50+ research assay kits. In 2020, they joined Nephrosant, Inc. as the Director of Research and Development. In this role, they achieved the development of the final components and necessary assay optimization to attain the required sensitivity and reproducibility of a Laboratory Developed Test (LDT) for quantifying the risk of kidney transplant rejections. In 2022, they joined PrognomiQ Inc as the Director of Assay Development and Operations.

Bob Zawada obtained their Bachelor of Science in Chemical Engineering from the University of Notre Dame from 1990 to 1994. Bob then went on to pursue a PhD in Chemical Engineering from Stanford University from 1994 to 1999. In addition, in August 2019, they obtained a Good Laboratory Practice certification from the CITI Program, a Division of BRANY. Bob is also currently enrolled in an Introduction to Genomic Technologies course at The Johns Hopkins University.